autologous blood and marrow transplantation - Blog Science ...

Giralt, Khouri, and Champlin
Table 1. Characteristics of patients undergoing minitransplant for AML and CML at
M.D. Anderson Cancer Center
n 26
Age (years) 60 (28-72)
Diagnosis and stage at BMT
AML
First relapse untreated 2
CR 2 2
Refractory relapse or >CR 2 9
MDS
Untreated 1
First relapse untreated
Refractory relapse or >CR 2
CML
First chronic phase 5
Transformed 4
Median time to transplant (days) 490 (77-3429)
Median no. of prior therapies 2 (1-3)
Preparative regimen
Flaglda 17
2CDA/AraC 9
Donor type and cell source
Sibling matched or 1 Ag mismatch 20/3
6/6 matched unrelated 2
Syngeneic 1
PBSC/BM 22/4
GVHD prophylaxis (twin excluded)
CSA or CSA/MP 19
FK/MTX 6 _
therapy with steroids alone or in addition to antithymocyte globulin (ATG).
Thirteen patients had neutrophil recovery a median of 10 days posttransplant
(range 9-18) and 11 achieved platelet transfusion independence a median of 12
days posttransplant (range 8-78). Ten patients achieved complete remission (80% donor cells either by
cytogenetics or molecular techniques, one patient had autologous reconstitution,
and two patients were inevaluable for chimerism either because of technical
difficulties or lack of difference in enzyme restriction pattern between donor and
recipient (syngeneic transplant). At 3 months posttransplant, six patients remained
in remission, four of whom had >80% donor cells by similar studies, and by 1 year,
613